BioCentury
ARTICLE | Clinical News

PreHistin cyanocobalamin: Phase III started

July 31, 2006 7:00 AM UTC

CLSC began a double-blind, placebo-controlled, U.S. Phase IIII trial in 800-1,000 patients. Patients will receive either placebo or 3.3 mg of sublingual PreHistin twice-daily for 3 weeks prior to the ...